CN1859846A - 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用 - Google Patents

白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用 Download PDF

Info

Publication number
CN1859846A
CN1859846A CNA2004800280172A CN200480028017A CN1859846A CN 1859846 A CN1859846 A CN 1859846A CN A2004800280172 A CNA2004800280172 A CN A2004800280172A CN 200480028017 A CN200480028017 A CN 200480028017A CN 1859846 A CN1859846 A CN 1859846A
Authority
CN
China
Prior art keywords
alkyl
group
pharmaceutically acceptable
chelerythrine
membered ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800280172A
Other languages
English (en)
Chinese (zh)
Inventor
A·F·T·阿恩斯坦
S·G·伯恩鲍母
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN1859846A publication Critical patent/CN1859846A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CNA2004800280172A 2003-09-26 2004-09-27 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用 Pending CN1859846A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/672,626 US20050070565A1 (en) 2003-09-26 2003-09-26 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
US10/672,626 2003-09-26

Publications (1)

Publication Number Publication Date
CN1859846A true CN1859846A (zh) 2006-11-08

Family

ID=34376422

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800280172A Pending CN1859846A (zh) 2003-09-26 2004-09-27 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用

Country Status (11)

Country Link
US (2) US20050070565A1 (enExample)
EP (1) EP1662875A4 (enExample)
JP (1) JP2007506784A (enExample)
CN (1) CN1859846A (enExample)
AU (1) AU2004275852A1 (enExample)
BR (1) BRPI0414816A (enExample)
CA (1) CA2540151A1 (enExample)
IL (1) IL174303A0 (enExample)
MX (1) MXPA06003423A (enExample)
NO (1) NO20061357L (enExample)
WO (1) WO2005030143A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080145351A1 (en) * 2000-04-20 2008-06-19 The Research Foundation Of State University Of New York Memory influencing protein
US7928070B2 (en) 2000-04-20 2011-04-19 The Research Foundation Of State University Of Ny Memory enhancing protein
WO2007089774A2 (en) * 2006-01-31 2007-08-09 Yale University Compositions and methods for treating cognitive disorders
US8362028B2 (en) * 2006-07-31 2013-01-29 Yale University Pseudobase benzo[c]phenanthridines with improved efficacy, stability and safety
WO2008048194A1 (en) * 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
CN101209043B (zh) * 2006-12-27 2011-08-10 长沙世唯科技有限公司 血根碱或白屈菜红碱在血吸虫病防治上的应用
WO2008118403A2 (en) * 2007-03-22 2008-10-02 Yale University Method of using a pkc inhibitor to reverse prefrontal cortical declines
US20120201908A1 (en) * 2009-08-19 2012-08-09 Lunera Equities, Lllp Method of treating bipolar disorder or depression using an antiestrogen
US20170189391A1 (en) * 2015-12-31 2017-07-06 Macau University of Science ang Technology Protein kinase C inhibitor for treating triple-negative breast cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683133A (en) * 1985-08-20 1987-07-28 Vipont Laboratories, Inc. Method for treating periodontal disease
US5747502A (en) * 1989-12-13 1998-05-05 Nippon Kayaku Kabushiki Kaisha Process for preparing benzo c!phenanthridinium derivatives, novel compounds prepared by said process, and antitumor agents
JP2784104B2 (ja) * 1991-08-06 1998-08-06 三菱電機株式会社 タイミングシミュレーションシステム
US5922571A (en) * 1997-03-06 1999-07-13 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein kinase C homolog
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
US6664266B2 (en) * 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors

Also Published As

Publication number Publication date
US20050070565A1 (en) 2005-03-31
CA2540151A1 (en) 2005-04-07
MXPA06003423A (es) 2006-06-27
WO2005030143A2 (en) 2005-04-07
BRPI0414816A (pt) 2006-11-14
WO2005030143A3 (en) 2005-09-15
NO20061357L (no) 2006-06-16
EP1662875A4 (en) 2009-04-15
IL174303A0 (en) 2006-08-01
US20100222376A1 (en) 2010-09-02
JP2007506784A (ja) 2007-03-22
AU2004275852A1 (en) 2005-04-07
EP1662875A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
CN1083448C (zh) 1-苯基-4-苄基哌嗪化合物多巴胺受体亚型的特异性配体(d4)
JP4698591B2 (ja) 非鎮静ａ−２アゴニスト１−（２，３−ジメチル−フェニル）−エチル−１、３−ジヒドロ−イミダゾール−２−チオン
JP6630374B2 (ja) τリン酸化を阻害する方法
KR102232625B1 (ko) 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
JP6684210B2 (ja) チロシン誘導体及びそれを含む組成物
US20100222376A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
RU2003115490A (ru) Амидные производные в качестве антагонистов nmda рецептора
JP2007505112A (ja) 改善された非沈静α２アゴニストを同定するための新規方法
CN1893948A (zh) 蕈毒碱性乙酰胆碱受体拮抗剂
RU2002131885A (ru) Антраниламиды и их применение в качестве лекарственных средств
JPH07509219A (ja) Ｈ↓３受容体アンタゴニストとしての４−［４’−ピペリジニルまたは３’−ピロリジニル］置換イミダゾールおよび治療上のその使用方法
CN105228622A (zh) 用于治疗多发性硬化的PPARγ激动剂
CN1204139C (zh) 神经性疼痛治疗剂
EP3503884B1 (en) Pharmaceutical composition for use in treating pruritus and/or itch
JP2015510898A (ja) 癌の治療のためのキナーゼ阻害剤
JP2024509265A (ja) 赤血球増加症を処置するための組成物および方法
US20240325382A1 (en) Compositions and methods for treating anemia associated with a ribosomal disorder
US20250295611A1 (en) Methods of treating 5ht2a receptor-mediated conditions
CN1146992A (zh) 中间体(r)-3-氨基-5-甲氧基苯并二氢吡喃的制备方法
RU2646475C2 (ru) Лечение диабета I и II типа
CN1753677A (zh) 降眼压剂
EP4117660B1 (en) Methods of modulating t-cell activation and treating chronic heart failure using carboranes
JP4362457B2 (ja) 神経因性疼痛治療剤
RU2005126459A (ru) Производные диазепана, используемые в качестве ингибиторов lfa

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061108